Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 10 de 10
1.
J Affect Disord ; 356: 535-544, 2024 Jul 01.
Article En | MEDLINE | ID: mdl-38657762

BACKGROUND: History of suicide attempt (SA) is the strongest predictor of a new SA and suicide. It is primordial to identify additional risk factors of suicide re-attempt. The aim of this study was to identify risk factors of suicide re-attempt in patients with recent SA followed for 2 years. METHODS: In this multicentric cohort of adult inpatients, the median of the index SA before inclusion was 10 days. Clinicians assessed a large panel of psychological dimensions using validated tools. Occurrence of a new SA or death by suicide during the follow-up was recorded. A cluster analysis was used to identify the dimensions that best characterized the population and a variable "number of personality traits" was created that included the three most representative traits: anxiety, anger, and anxious lability. Risk factors of re-attempt were assessed with adjusted Cox regression models. RESULTS: Among the 379 patients included, 100 (26.4 %) re-attempted suicide and 6 (1.6 %) died by suicide. The two major risk factors of suicide re-attempt were no history of violent SA and presenting two or three personality traits among trait anxiety, anger and anxious lability. LIMITATIONS: It was impossible to know if treatment change during follow-up occur before or after the re-attempt. DISCUSSION: One of the most important predictors of re-attempt in suicide attempters with mood disorders, was the presence of three personality traits (anger, anxiety, and anxious lability). Clinicians should provide close monitoring to patients presenting these traits and proposed treatments specifically targeting these dimensions, especially anxiety.


Anger , Suicide, Attempted , Humans , Male , Female , Suicide, Attempted/statistics & numerical data , Suicide, Attempted/psychology , Risk Factors , Adult , Prospective Studies , Middle Aged , Anxiety/psychology , Anxiety/epidemiology , Personality , Recurrence , Mood Disorders/psychology , Mood Disorders/epidemiology
3.
Front Pharmacol ; 12: 615695, 2021.
Article En | MEDLINE | ID: mdl-33767623

At the time of writing (December 2020), coronavirus disease 2019 (COVID-19) has already caused more than one million deaths worldwide, and therefore, it is imperative to find effective treatments. The "cytokine storm" induced by Severe Acute Respiratory Syndrome-Coronavirus type 2 (SARS-CoV-2) is a good target to prevent disease worsening, as indicated by the results obtained with tocilizumab and dexamethasone. SARS-CoV-2 can also invade the brain and cause neuro-inflammation with dramatic neurological manifestations, such as viral encephalitis. This could lead to potentially incapacitating long-term consequences, such as the development of psychiatric disorders, as previously observed with SARS-CoV. Several pathways/mechanisms could explain the link between viral infection and development of psychiatric diseases, especially neuro-inflammation induced by SARS-CoV-2. Therefore, it is important to find molecules with anti-inflammatory properties that penetrate easily into the brain. For instance, some antidepressants have anti-inflammatory action and pass easily through the blood brain barrier. Among them, clomipramine has shown very strong anti-inflammatory properties in vitro, in vivo (animal models) and human studies, especially in the brain. The aim of this review is to discuss the potential application of clomipramine to prevent post-infectious mental complications. Repositioning and testing antidepressants for COVID-19 management could help to reduce peripheral and especially central inflammation and to prevent the acute and particularly the long-term consequences of SARS-CoV-2 infection.

4.
Curr Psychiatry Rep ; 23(4): 16, 2021 03 03.
Article En | MEDLINE | ID: mdl-33660116

PURPOSE OF REVIEW: The aim of this review was to analyze COVID-19 effect on the biological features of suicidal vulnerability and its interaction with suicide-related biological pathways. We carried out a narrative review of international publications on the interactions of COVID-19 with the biological bases of suicide. RECENT FINDINGS: We hypothesize that SARS-CoV-2 interacts with multiple biological processes that underlie suicidal behavior, such as the renin-angiotensin system, nicotinic receptors, and central and systemic inflammation. Social distancing measures may also worsen subjective or objective social disconnection, thus increasing the risk of suicide. Interestingly, the drugs used to prevent suicide could be promising options to counteract brain damage caused by this coronavirus. SARS-CoV-2 interacts with multiple biological pathways involved in suicide and opens a new window for understanding the suicidal process. The development of suicide prevention treatments in the context of a pandemic may benefit from knowledge on these interactions.


COVID-19 , Coronavirus Infections , Suicide , Coronavirus Infections/epidemiology , Humans , Pandemics , SARS-CoV-2
5.
Transl Psychiatry ; 10(1): 320, 2020 09 20.
Article En | MEDLINE | ID: mdl-32952155

The prescription of antidepressant drugs is one of the most frequently used strategies to prevent suicide and suicidal behavior. However, some patients develop suicidal ideation at antidepressant treatment onset, a phenomenon known as treatment-emergent suicidal ideation (TESI). Few studies have explored TESI pharmacogenomics. As the Hypothalamic-Pituitary-Adrenal (HPA) axis might be implicated in suicidal behavior, we assessed the relationship between TESI and single nucleotide polymorphisms (SNPs) in the HPA axis-implicated NR3C1 (n = 7 SNPs), FKBP5 (n = 5 SNPs), AVPR1B (n = 1 SNPs), CRHR1 (n = 1 SNPs), and SKA2 (n = 1 SNPs) genes, in a sample of 3566 adult outpatients with depression for whom an antidepressant treatment was introduced. General practitioners and psychiatrists throughout France followed participants for 6 weeks after the initial prescription of tianeptine, an antidepressant molecule showing mu agonism. Suicidal ideation was assessed with item 10 of the Montgomery-Åsberg Depression Rating Scale (item dedicated to suicidal ideation) at baseline, and at week 2, 4, and 6 of treatment. Within the informative sample, 112 patients reported TESI and 384 did not. TESI was significantly associated with the TT genotype of the SNP rs6902321 in FKBP5 (OR = 1.76, 95% CI = [1.07; 2.90]; p-value = 0.03) and the GG/AG genotype of the SNP rs7208505 in SKA2 (OR = 1.85, 95% CI = [1.03;3.33]; p-value = 0.04). These associations were not significant after multiple test correction. Nevertheless, our results suggest a possible involvement of HPA axis elements in treatment-emergent suicidal ideation (TESI).


Hypothalamo-Hypophyseal System , Suicidal Ideation , Adult , Antidepressive Agents/therapeutic use , Chromosomal Proteins, Non-Histone , France , Humans , Pituitary-Adrenal System
8.
Sci Rep ; 9(1): 2569, 2019 02 22.
Article En | MEDLINE | ID: mdl-30796320

Antidepressants have been the object of an international controversy for about thirty years. Some patients are inclined to develop suicidal ideation (SI) at antidepressant onset; this phenomenon is known as Treatment Emergent Suicidal Ideation (TESI), and it has conducted regulatory bodies to prompt warnings on antidepressants. Since, few studies have explored the pharmacogenomics of TESI. Given the growing body of evidence connecting the opioidergic system with suicidal behavior (particularly mu opioid receptor (MOR)), we decided to examine the relationship between two genetic polymorphisms (SNPs) in the opioidergic system and TESI in a sample of 3566 adult depressed outpatients. General practitioners and psychiatrists throughout France followed participants for 6 weeks after an initial prescription of tianeptine, an antidepressant treatment with mu agonism. Suicidal ideation was assessed with the item 10 of the Montgomery-Asberg Depression Rating Scale (item dedicated to SI) at baseline, and after 2 weeks, 4 weeks and 6 weeks. We analysed rs1799971 from the OPRM1 gene and rs105660 from the OPRK1 gene. Within the sample, 112 patients reported TESI while 384 did not. We found a significant association between AA genotype of rs1799971 and TESI even after adjustment for potential cofounders (OR = 1.93, 95% CI = [1.07; 3.49]; p-value = 0.03). On the other hand there were no significant association between rs1799971 and rs105560 with worsening of suicidal ideation or lifetime suicide attempts. Nevertheless, our results suggest a possible involvement of opioidergic system in TESI.


Antidepressive Agents/administration & dosage , Depression/genetics , Polymorphism, Single Nucleotide , Receptors, Opioid, mu/genetics , Adult , Antidepressive Agents/adverse effects , Depression/drug therapy , Depression/pathology , Female , Humans , Male , Middle Aged , Prospective Studies , Suicidal Ideation
9.
J Psychiatr Res ; 96: 167-170, 2018 01.
Article En | MEDLINE | ID: mdl-29073492

Worsening of suicidal ideation during the first weeks of antidepressant treatment is a poorly understood phenomenon that prompted regulatory bodies to issue specific warnings. To better understand the causes of this phenomenon, this study compared the risk of suicidal ideation worsening in patients taking different types of antidepressant medications. To this aim, 4017 depressed adult outpatients were followed by general practitioners and psychiatrists throughout France for 6 weeks after prescription of an antidepressant treatment. The main study outcomes were to monitor changes (worsening or improvement) in suicidal ideation between baseline (treatment onset) and the study end (week 6) and to determine the remission rates according to the treatment type. Depression severity was assessed with the patient-administered Hospital Anxiety and Depression Scale and suicidal ideation with the 9-item Montgomery-Asberg Depression Rating Scale and the Hopelessness Scale. Use of tianeptine, a mu-opioid receptor agonist was significantly associated with a lower risk of suicidal ideation worsening compared with other antidepressants in the first 6 weeks of treatment. Conversely, remission rates were not significantly affected by the treatment type. Our results highlight a potential interest of opioid agonists to reduce the risk of worsening of suicidal ideation at antidepressant initiation.


Antidepressive Agents, Tricyclic/therapeutic use , Depressive Disorder, Major/drug therapy , Suicidal Ideation , Thiazepines/therapeutic use , Antidepressive Agents, Tricyclic/adverse effects , Depressive Disorder, Major/psychology , Female , Follow-Up Studies , France , Humans , Male , Middle Aged , Odds Ratio , Psychiatric Status Rating Scales , Severity of Illness Index , Thiazepines/adverse effects , Time Factors , Treatment Outcome
10.
Rev. chil. infectol ; 20(2): 133-135, 2003. tab
Article Es | LILACS | ID: lil-365880

Streptococcus bovis forma parte de la flora intestinal humana. Las infecciones clínicas mes importantes causadas por este microorganismo son bacteriemia y endocarditis, estando la primera asociada con patologías intestinales, especialmente con enfermedades malignas como cancer o poliposis de colon. Las infecciones de diversos sitios anatómicos, aunque infrecuentes, pueden en ciertas instancias ser la sola clave de la presencia de malignidad. Estas infecciones se relacionan con la invasión de tejidos u órganos próximos al tumor o pueden ser secundarias a una siembra a distancia, a través de la bacteriemia originada en tejido tumoral necrótico. En este reporte se describe el caso de una paciente con un quiste de ovario abscedado en el que se aisló Streptococcus bovis I y Enterobacter cloacae. Durante el tratamiento se diagnosticó cancer de colon


Humans , Female , Middle Aged , Colonic Neoplasms , Streptococcal Infections/diagnosis , Streptococcal Infections/drug therapy , Abdominal Abscess , Ovary
...